Core Insights - The company emphasizes that research and development (R&D) is the core driving force for its growth, aiming for precise and efficient R&D [1] - The company focuses on key therapeutic areas such as cardiovascular and metabolic diseases, establishing a systematic layout for global patent barrier innovation pipelines [1] - The self-developed Class 1 small molecule innovative drug HS387 has received clinical implied approval from NMPA, officially entering the clinical development stage [1] - The company is accelerating the introduction of clinical-stage pipelines to enrich its product lineup and address more unmet clinical needs [1]